메뉴 건너뛰기




Volumn 14, Issue 14, 2013, Pages 1933-1947

Current strategies for the treatment of complicated intraabdominal infections

Author keywords

Abdominal; Complicated; Infection; Intraabdominal; Peritonitis

Indexed keywords

ACHN 4980; AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; ERAVACYCLINE; ERTAPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MK 7655; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PLAZOMICIN; QUINOLONE DERIVATIVE; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

EID: 84884247435     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.821109     Document Type: Review
Times cited : (14)

References (117)
  • 1
    • 73649114948 scopus 로고    scopus 로고
    • Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the surgical infection society and the infectious diseases society of america
    • Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64
    • (2010) Clin Infect Dis , vol.50 , pp. 133-164
    • Solomkin, J.S.1    Mazuski, J.E.2    Bradley, J.S.3
  • 2
    • 77951627860 scopus 로고    scopus 로고
    • Diagnosis and management of complicated intra-abdominal infections in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of North America
    • Solomkin JS, Mazuski JE, Bradley J, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of North America. Surg Infect (Larchmt) 2010;11:79-109
    • (2010) Surg Infect (Larchmt , vol.11 , pp. 79-109
    • Solomkin, J.S.1    Mazuski, J.E.2    Bradley, J.3
  • 3
    • 35349019173 scopus 로고    scopus 로고
    • Invasive methicillin-resistant staphylococcus aureus infections in the united states
    • Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71
    • (2007) JAMA , vol.298 , pp. 1763-1771
    • Klevens, R.M.1    Morrison, M.A.2    Nadle, J.3
  • 4
    • 0036920011 scopus 로고    scopus 로고
    • Microbiology of polymicrobial abscesses and implications for therapy
    • Brook I. Microbiology of polymicrobial abscesses and implications for therapy. J Antimicrob Chemother 2002;50:805-10
    • (2002) J Antimicrob Chemother , vol.50 , pp. 805-810
    • Brook, I.1
  • 5
    • 3042645804 scopus 로고    scopus 로고
    • Intra-abdominal infections: Review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy
    • Goldstein EJC, Snydman DR. Intra-abdominal infections: Review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004;53:ii29-36
    • (2004) J Antimicrob Chemother , vol.53
    • Goldstein, E.J.C.1    Snydman, D.R.2
  • 6
    • 0035503611 scopus 로고    scopus 로고
    • The microbiology of postoperative peritonitis
    • Roehrborn A, Thomas L, Potreck O, et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001;33:1513-19
    • (2001) Clin Infect Dis , vol.33 , pp. 1513-1519
    • Roehrborn, A.1    Thomas, L.2    Potreck, O.3
  • 7
    • 0036797245 scopus 로고    scopus 로고
    • Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis
    • Sotto A, Lefrant JY, Fabbro-Peray P, et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002;50:569-76
    • (2002) J Antimicrob Chemother , vol.50 , pp. 569-576
    • Sotto, A.1    Lefrant, J.Y.2    Fabbro-Peray, P.3
  • 8
    • 62549100893 scopus 로고    scopus 로고
    • Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study
    • Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009;63:785-94
    • (2009) J Antimicrob Chemother , vol.63 , pp. 785-794
    • Montravers, P.1    Lepape, A.2    Dubreuil, L.3
  • 9
    • 67649556902 scopus 로고    scopus 로고
    • Choosing antibiotics for intra-abdominal infections: What do we mean by "high risk"?
    • Swenson BR, Metzger R, Hedrick TL, et al. Choosing antibiotics for intra-abdominal infections: What do we mean by "high risk"̈Surg Infect (Larchmt) 2009;10:29-39
    • (2009) Surg Infect (Larchmt , vol.10 , pp. 29-39
    • Swenson, B.R.1    Metzger, R.2    Hedrick, T.L.3
  • 10
    • 84861204086 scopus 로고    scopus 로고
    • Complicated intra-abdominal infections in europe: Preliminary data from the first three months of the ciao study
    • Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in Europe: Preliminary data from the first three months of the CIAO Study. World J Emerg Surg 2012;7:15
    • (2012) World J Emerg Surg , vol.7 , pp. 15
    • Sartelli, M.1    Catena, F.2    Ansaloni, L.3
  • 11
    • 0036122122 scopus 로고    scopus 로고
    • Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis
    • Sitges-Serra A, López MJ, Girvent M, et al. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002;89:361-7
    • (2002) Br J Surg , vol.89 , pp. 361-367
    • Sitges-Serra, A.1    López, M.J.2    Girvent, M.3
  • 12
    • 66249085209 scopus 로고    scopus 로고
    • Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: A French prospective observational multicenter study
    • Gauzit R, Péan Y, Barth X, et al. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: A French prospective observational multicenter study. Surg Infect (Larchmt) 2009;10:119-27
    • (2009) Surg Infect (Larchmt , vol.10 , pp. 119-127
    • Gauzit, R.1    Péan, Y.2    Barth, X.3
  • 13
    • 29944440422 scopus 로고    scopus 로고
    • Candida as a risk factor for mortality in peritonitis
    • Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006;34:646-52
    • (2006) Crit Care Med , vol.34 , pp. 646-652
    • Montravers, P.1    Dupont, H.2    Gauzit, R.3
  • 14
    • 0036186128 scopus 로고    scopus 로고
    • Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations
    • Sandven P, Qvist H, Skovlund E, et al. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002;30:541-7
    • (2002) Crit Care Med , vol.30 , pp. 541-547
    • Sandven, P.1    Qvist, H.2    Skovlund, E.3
  • 15
    • 77955649358 scopus 로고    scopus 로고
    • Epidemiologic trends occurrence of extended-spectrum betalactamase production and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the smart study
    • Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. Epidemiologic trends, occurrence of extended-spectrum betalactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the SMART study. Surg Infect (Larchmt) 2010;11:371-8
    • (2010) Surg Infect (Larchmt , vol.11 , pp. 371-378
    • Hawser, S.P.1    Bouchillon, S.K.2    Hoban, D.J.3    Badal, R.E.4
  • 16
    • 0029071785 scopus 로고
    • A functional classification scheme for beta-lactamases and its correlation with molecular structure
    • Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 1211-1233
    • Bush, K.1    Jacoby, G.A.2    Medeiros, A.A.3
  • 17
    • 21244488243 scopus 로고    scopus 로고
    • Revised Ambler classification of beta-lactamases
    • Hall BG, Barlow M. Revised Ambler classification of beta-lactamases. J Antimicrob Chemother 2005;55:1050-1
    • (2005) J Antimicrob Chemother , vol.55 , pp. 1050-1051
    • Hall, B.G.1    Barlow, M.2
  • 18
    • 79952420498 scopus 로고    scopus 로고
    • Current concepts in antimicrobial therapy against resistant gram-negative organisms: Extended-spectrum betalactamase- producing enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant pseudomonas aeruginosa
    • Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: Extended-spectrum betalactamase- producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011;86:250-9
    • (2011) Mayo Clin Proc , vol.86 , pp. 250-259
    • Kanj, S.S.1    Kanafani, Z.A.2
  • 19
    • 27144490073 scopus 로고    scopus 로고
    • Extended-spectrum beta-lactamases: A clinical update
    • Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Micribiol Rev 2005;18:657-86
    • (2005) Clin Micribiol Rev , vol.18 , pp. 657-686
    • Paterson, D.L.1    Bonomo, R.A.2
  • 20
    • 21244488639 scopus 로고    scopus 로고
    • In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 study for monitoring antimicrobial resistance trends (smart
    • Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-73
    • (2005) J Antimicrob Chemother , vol.55 , pp. 965-973
    • Paterson, D.L.1    Rossi, F.2    Baquero, F.3
  • 21
    • 77955649358 scopus 로고    scopus 로고
    • Epidemiologic trends occurrence of extended-spectrum betalactamase production and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the smart study
    • Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. Epidemiologic trends, occurrence of extended-spectrum betalactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the SMART study. Surg Infect (Larchmt) 2010;11:371-8
    • (2010) Surg Infect (Larchmt , vol.11 , pp. 371-378
    • Hawser, S.P.1    Bouchillon, S.K.2    Hoban, D.J.3    Badal, R.E.4
  • 22
    • 78249245418 scopus 로고    scopus 로고
    • Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in china: The 2002-2009 study for monitoring antimicrobial resistance trends (smart
    • Yang Q, Wang H, Chen M, et al. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: The 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2010;36:507-12
    • (2010) Int J Antimicrob Agents , vol.36 , pp. 507-512
    • Yang, Q.1    Wang, H.2    Chen, M.3
  • 23
    • 78751572709 scopus 로고    scopus 로고
    • Antimicrobial susceptibility of intraabdominal gram-negative bacilli from europe: Smart europe 2008
    • Hawser S, Hoban D, Bouchillon S, et al. Antimicrobial susceptibility of intraabdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011;30:173-9
    • (2011) Eur J Clin Microbiol Infect Dis , vol.30 , pp. 173-179
    • Hawser, S.1    Hoban, D.2    Bouchillon, S.3
  • 24
    • 79960325246 scopus 로고    scopus 로고
    • Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates
    • Hawser SP, Bouchillon SK, Lascols C, et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 2011;55:3917-21
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 3917-3921
    • Hawser, S.P.1    Bouchillon, S.K.2    Lascols, C.3
  • 25
    • 84857700015 scopus 로고    scopus 로고
    • Trending eight years of in vitro activity of ertapenem and comparators against escherichia coli from intra-abdominal infections in north america-smart 2002-2009
    • Hawser SP, Badal RE, Bouchillon SK, Hoban DJ. Trending eight years of in vitro activity of ertapenem and comparators against Escherichia coli from intra-abdominal infections in North America-SMART 2002-2009. J Chemother 2011;23:266-72
    • (2011) J Chemother , vol.23 , pp. 266-272
    • Hawser, S.P.1    Badal, R.E.2    Bouchillon, S.K.3    Hoban, D.J.4
  • 26
    • 84856053228 scopus 로고    scopus 로고
    • Susceptibility of european escherichia coli clinical isolates from intra-abdominal infections extended-spectrum beta-lactamse occurrence resistance distribution and molecular characterization of ertapenem-resistant isolates (smart 2008-2009
    • Hawser SP, Bouchillon SK, Lascols C, et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum beta-lactamse occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect 2012;18:253-9
    • (2012) Clin Microbiol Infect , vol.18 , pp. 253-259
    • Hawser, S.P.1    Bouchillon, S.K.2    Lascols, C.3
  • 27
    • 84866257739 scopus 로고    scopus 로고
    • Low frequency of ertapenem-resistant intra-abdominal isolates of escherichia coli from latin america: Susceptibility, esbl-occurrence, and molecular chacterisation (smart 2008-2009
    • Hawser SP, Bouchilon SK, Hoban DJ, et al. Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: Susceptibility, ESBL-occurrence, and molecular chacterisation (SMART 2008-2009). J Chemother 2012;24:6-11
    • (2012) J Chemother , vol.24 , pp. 6-11
    • Hawser, S.P.1    Bouchilon, S.K.2    Hoban, D.J.3
  • 28
    • 84872897846 scopus 로고    scopus 로고
    • Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: Smart 2002-2010
    • Hawser SP, Badal RE, Bouchillon SK, et al. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int J Antimicrob Agents 2013;41:224-8
    • (2013) Int J Antimicrob Agents , vol.41 , pp. 224-228
    • Hawser, S.P.1    Badal, R.E.2    Bouchillon, S.K.3
  • 29
    • 84863446793 scopus 로고    scopus 로고
    • Impact of revised clsi breakpoints for susceptibility to third-generation cephalosporins and carbapenems among enterobacteriaceae isolates in the asia-pacific region: Results from the study for monitoring antimicrobial resistance trends (smart), 2002-2010
    • Suppl
    • Huang CC, Chen YS, Toh HS, et al. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. Int J Antimicrob Agents 2012;40(Suppl):S4-10
    • (2012) Int J Antimicrob Agents , vol.40
    • Huang, C.C.1    Chen, Y.S.2    Toh, H.S.3
  • 30
    • 84863446793 scopus 로고    scopus 로고
    • Impact of revised clsi breakpoints for susceptibility to third-generation cephalosporins and carbapenems among enterobacteriaceae isolates in the asia-pacific region: Results from the study for monitoring antimicrobial resistance trends (smart), 2002-2010
    • Suppl
    • Huang CC, Chen YS, Toh HS, et al. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. Int J Antimicrob Agents 2012;40(Suppl):S4-10
    • (2012) Int J Antimicrob Agents , vol.40
    • Huang, C.C.1    Chen, Y.S.2    Toh, H.S.3
  • 31
    • 84872025829 scopus 로고    scopus 로고
    • Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: First report of OXA-48-Like Enzymes in North America
    • Lascols C, Peirano G, Hackel M, et al. Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: First report of OXA-48-Like Enzymes in North America. Antimicrob Agents Chemother 2013;57:130-6
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 130-136
    • Lascols, C.1    Peirano, G.2    Hackel, M.3
  • 32
    • 79956007427 scopus 로고    scopus 로고
    • Trends in carbapenemase-producing Escherichia coli and klebsiella spp from europe and the americas: Report from the sentry antimicrobial surveillance programme 2007-09
    • Castanheira M, Mendes RE, Woosley LN, Jones RN. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. From Europe and the Americas: Report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 2011;66:1409-11
    • (2011) J Antimicrob Chemother , vol.66 , pp. 1409-1411
    • Castanheira, M.1    Mendes, R.E.2    Woosley, L.N.3    Jones, R.N.4
  • 33
    • 34547422759 scopus 로고    scopus 로고
    • Carbapenemases: The versatile beta-lactamases
    • Queenan AM, Bush K. Carbapenemases: The versatile beta-lactamases. Clin Microbiol Rev 2007;20:440-58
    • (2007) Clin Microbiol Rev , vol.20 , pp. 440-458
    • Queenan, A.M.1    Bush, K.2
  • 34
    • 84867166640 scopus 로고    scopus 로고
    • Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: An evolving crisis of global dimensions
    • Tzouvelekis S, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: An evolving crisis of global dimensions. Clin Microbiol Rev 2012;25:682
    • (2012) Clin Microbiol Rev , vol.25 , pp. 682
    • Tzouvelekis, S.1    Markogiannakis, A.2    Psichogiou, M.3
  • 35
    • 79957581336 scopus 로고    scopus 로고
    • Status report on carbapenemases: Challenges and prospects
    • Patel G, Bonomo RA. Status report on carbapenemases: Challenges and prospects. Expert Rev Anti Infect Ther 2011;9:555-70
    • (2011) Expert Rev Anti Infect Ther , vol.9 , pp. 555-570
    • Patel, G.1    Bonomo, R.A.2
  • 37
    • 33744481534 scopus 로고    scopus 로고
    • First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-betalactamase, IMP-18
    • Hanson ND, Hossain A, Buck L, et al. First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-betalactamase, IMP-18. Antimicrob Agents Chemother 2006;50:2272-3
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 2272-2273
    • Hanson, N.D.1    Hossain, A.2    Buck, L.3
  • 38
    • 0347992025 scopus 로고    scopus 로고
    • Blavim-7, an evolutionarily distinct metallo-beta-lactamase gene in a pseudomonas aeruginosa isolate from the united states
    • Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 2004;48:329-32
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 329-332
    • Toleman, M.A.1    Rolston, K.2    Jones, R.N.3    Walsh, T.R.4
  • 39
    • 23044462515 scopus 로고    scopus 로고
    • First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States
    • Lolans K, Queenan AM, Bush K, et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005;49:3538-40
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 3538-3540
    • Lolans, K.1    Queenan, A.M.2    Bush, K.3
  • 40
    • 77949483649 scopus 로고    scopus 로고
    • Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis
    • Augustin P, Kermarrec N, Muller-Serieys C, et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010;14:R20
    • (2010) Crit Care , vol.14
    • Augustin, P.1    Kermarrec, N.2    Muller-Serieys, C.3
  • 41
    • 33748335409 scopus 로고    scopus 로고
    • Factors associated with multidrug-resistant bacteria in secondary peritonitis: Impact on antibiotic therapy
    • Seguin P, Laviolle B, Chanavaz C, et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: Impact on antibiotic therapy. Clin Microbiol Infect 2006;12:980-5
    • (2006) Clin Microbiol Infect , vol.12 , pp. 980-985
    • Seguin, P.1    Laviolle, B.2    Chanavaz, C.3
  • 42
    • 77950207293 scopus 로고    scopus 로고
    • Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care
    • Seguin P, Fédun Y, Laviolle B, et al. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother 2010;65:342-6
    • (2010) J Antimicrob Chemother , vol.65 , pp. 342-346
    • Seguin, P.1    Fédun, Y.2    Laviolle, B.3
  • 43
    • 4444326184 scopus 로고    scopus 로고
    • Intra-abdominal infections
    • Marshall JC. Intra-abdominal infections. Microbes Infect 2004;6:1015-25
    • (2004) Microbes Infect , vol.6 , pp. 1015-1025
    • Marshall, J.C.1
  • 44
    • 84873339299 scopus 로고    scopus 로고
    • Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock
    • Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med 2013;41:580-637
    • (2013) Crit Care Med , vol.41 , pp. 580-637
    • Dellinger, R.P.1    Levy, M.M.2    Rhodes, A.3
  • 45
    • 8444234653 scopus 로고    scopus 로고
    • Source control in the management of severe sepsis and septic shock: An evidence-based review
    • Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: An evidence-based review. Crit Care Med 2004;32(Suppl11):S513-26
    • (2004) Crit Care Med , vol.32 , Issue.SUPPL. 11
    • Marshall, J.C.1    Maier, R.V.2    Jimenez, M.3    Dellinger, E.P.4
  • 46
    • 0029798842 scopus 로고    scopus 로고
    • Predictors of outcome in patients with postoperative intra-abdominal infection
    • Grunau G, Heemken R, Hau T. Predictors of outcome in patients with postoperative intra-abdominal infection. Eur J Surg 1996;162:619-25
    • (1996) Eur J Surg , vol.162 , pp. 619-625
    • Grunau, G.1    Heemken, R.2    Hau, T.3
  • 47
    • 0032930613 scopus 로고    scopus 로고
    • Risk factors associated with intra-abdominal infections: A prospective multicenter study
    • Wacha H, Hau T, Dittmer R, et al. Risk factors associated with intra-abdominal infections: A prospective multicenter study. Langenbecks Arch Surg 1999;384:24-32
    • (1999) Langenbecks Arch Surg , vol.384 , pp. 24-32
    • Wacha, H.1    Hau, T.2    Dittmer, R.3
  • 48
    • 0042243576 scopus 로고    scopus 로고
    • Factors affecting mortality in generalized postoperative peritonitis: Multivariate analysis in 96 patients
    • Mulier S, Penninckx F, Verwaest C, et al. Factors affecting mortality in generalized postoperative peritonitis: Multivariate analysis in 96 patients. World J Surg 2003;27:379-84
    • (2003) World J Surg , vol.27 , pp. 379-384
    • Mulier, S.1    Penninckx, F.2    Verwaest, C.3
  • 49
    • 84884272122 scopus 로고    scopus 로고
    • Characteristics of intra-abdominal infections (IAI) with an associated bacteremia in patients with severe sepsis and septic shock
    • SUPPL
    • Tellor B, High E, Skrupky L, et al. Characteristics of intra-abdominal infections (IAI) with an associated bacteremia in patients with severe sepsis and septic shock. Crit Care Med 2012;40(Suppl):680
    • (2012) Crit Care Med , vol.40 , pp. 680
    • Tellor, B.1    High, E.2    Skrupky, L.3
  • 50
    • 27744454870 scopus 로고    scopus 로고
    • Percutaneous drainage of 300 intraperitoneal abscesses with long-term follow-up
    • Akinci D, Akhan O, Ozmen MN, et al. Percutaneous drainage of 300 intraperitoneal abscesses with long-term follow-up. Cardiovasc Intervent Radiol 2005;28:744-50
    • (2005) Cardiovasc Intervent Radiol , vol.28 , pp. 744-750
    • Akinci, D.1    Akhan, O.2    Ozmen, M.N.3
  • 51
    • 13444274702 scopus 로고    scopus 로고
    • Current concepts of percutaneous abscess drainage in postoperative retention
    • Theisen J, Bartels H, Weiss W, et al. Current concepts of percutaneous abscess drainage in postoperative retention. J Gastrointest Surg 2005;9:280-3
    • (2005) J Gastrointest Surg , vol.9 , pp. 280-283
    • Theisen, J.1    Bartels, H.2    Weiss, W.3
  • 52
    • 0036886276 scopus 로고    scopus 로고
    • CT-guided percutaneous drainage of intra-abdominal abscesses: APACHE III score stratification of 1-year results
    • Betsch A, Wiskirchen J, Trübenbach J, et al. CT-guided percutaneous drainage of intra-abdominal abscesses: APACHE III score stratification of 1-year results. Eur Radiol 2002;12:2883-9
    • (2002) Eur Radiol , vol.12 , pp. 2883-2889
    • Betsch, A.1    Wiskirchen, J.2    Trübenbach, J.3
  • 53
    • 67650712234 scopus 로고    scopus 로고
    • Acute complicated diverticulitis managed by laparoscopic lavage
    • Alamili M, Gögenur I, Rosenberg J. Acute complicated diverticulitis managed by laparoscopic lavage. Dis Colon Rectum 2009;52:1345-9
    • (2009) Dis Colon Rectum , vol.52 , pp. 1345-1349
    • Alamili, M.1    Gögenur, I.2    Rosenberg, J.3
  • 54
    • 0027385004 scopus 로고
    • 'Damage control': An approach for improved survival in exsanguinating penetrating abdominal injury
    • Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': An approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 1993;35:375-83
    • (1993) J Trauma , vol.35 , pp. 375-383
    • Rotondo, M.F.1    Schwab, C.W.2    McGonigal, M.D.3
  • 55
    • 78650182268 scopus 로고    scopus 로고
    • Outcomes of damage-control celiotomy in elderly nontrauma patients with intra-abdominal catastrophes
    • Subramanian A, Balentine C, Palacio CH. Outcomes of damage-control celiotomy in elderly nontrauma patients with intra-abdominal catastrophes. Am J Surg 2010;200:783-9
    • (2010) Am J Surg , vol.200 , pp. 783-789
    • Subramanian, A.1    Balentine, C.2    Palacio, C.H.3
  • 56
    • 77956216546 scopus 로고    scopus 로고
    • Damage control in trauma and abdominal sepsis
    • Suppl
    • Waibel BH, Rotondo MR. Damage control in trauma and abdominal sepsis. Crit Care Med 2010;38(Suppl):S421-30
    • (2010) Crit Care Med , vol.38
    • Waibel, B.H.1    Rotondo, M.R.2
  • 57
    • 34548106627 scopus 로고    scopus 로고
    • Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis A randomized trial
    • Van Ruler O, Mahler CW, Boer KR, et al. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis. A randomized trial. JAMA 2007;298:865-73
    • (2007) JAMA , vol.298 , pp. 865-873
    • Van Ruler, O.1    Mahler, C.W.2    Boer, K.R.3
  • 58
    • 0029833749 scopus 로고    scopus 로고
    • Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy
    • Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-94
    • (1996) Clin Infect Dis , vol.23 , pp. 486-494
    • Montravers, P.1    Gauzit, R.2    Muller, C.3
  • 59
    • 84861142935 scopus 로고    scopus 로고
    • Epidemiology and prognostic determinants of bacteraemic biliary tract infection
    • Ortega M, Marco F, Soriano A, et al. Epidemiology and prognostic determinants of bacteraemic biliary tract infection. J Antimicrob Chemother 2012;67:1508-13
    • (2012) J Antimicrob Chemother , vol.67 , pp. 1508-1513
    • Ortega, M.1    Marco, F.2    Soriano, A.3
  • 60
    • 4644296739 scopus 로고    scopus 로고
    • Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery
    • Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682-7
    • (2004) Eur J Clin Microbiol Infect Dis , vol.23 , pp. 682-687
    • Krobot, K.1    Yin, D.2    Zhang, Q.3
  • 61
    • 33744527833 scopus 로고    scopus 로고
    • Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock
    • 2154
    • Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96 2154
    • (2006) Crit Care Med , vol.34 , pp. 1589-1596
    • Kumar, A.1    Roberts, D.2    Wood, K.E.3
  • 62
    • 79954514875 scopus 로고    scopus 로고
    • Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines-A commentary and an alternative European approach to clinical definitions
    • Eckmann C, Dryden M, Montravers P, et al. Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines-a commentary and an alternative European approach to clinical definitions. Eur J Med Res 2011;16:115-26
    • (2011) Eur J Med Res , vol.16 , pp. 115-126
    • Eckmann, C.1    Dryden, M.2    Montravers, P.3
  • 63
    • 84871994820 scopus 로고    scopus 로고
    • 2013 WSES guidelines for management of intra-abdominal infections
    • Sartelli M, Viale P, Catena F, et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg 2013;8:3
    • (2013) World J Emerg Surg , vol.8 , pp. 3
    • Sartelli, M.1    Viale, P.2    Catena, F.3
  • 64
    • 34248334196 scopus 로고    scopus 로고
    • Comparative review of the carbapenems
    • Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-52
    • (2007) Drugs , vol.67 , pp. 1027-1052
    • Zhanel, G.G.1    Wiebe, R.2    Dilay, L.3
  • 65
    • 33644582754 scopus 로고    scopus 로고
    • Candida in the peritoneum: Passenger or pathogeñ
    • Rex JH. Candida in the peritoneum: Passenger or pathogen̈Crit Care Med 2006;34:902-3
    • (2006) Crit Care Med , vol.34 , pp. 902-903
    • Rex, J.H.1
  • 66
    • 33750598985 scopus 로고    scopus 로고
    • Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing
    • Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006;12:1209-13
    • (2006) Emerg Infect Dis , vol.12 , pp. 1209-1213
    • Tenover, F.C.1    Kalsi, R.K.2    Williams, P.P.3
  • 67
    • 84858627056 scopus 로고    scopus 로고
    • Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens
    • Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012;56:2108-13
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 2108-2113
    • Qureshi, Z.A.1    Paterson, D.L.2    Potoski, B.A.3
  • 68
    • 84866072596 scopus 로고    scopus 로고
    • Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K pneumoniae: Importance of combination therapy
    • Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012;55:943-50
    • (2012) Clin Infect Dis , vol.55 , pp. 943-950
    • Tumbarello, M.1    Viale, P.2    Viscoli, C.3
  • 69
    • 67749145541 scopus 로고    scopus 로고
    • Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria
    • Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 3430-3436
    • Plachouras, D.1    Karvanen, M.2    Friberg, L.E.3
  • 70
    • 79959248672 scopus 로고    scopus 로고
    • Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients
    • Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 3284-3294
    • Garonzik, S.M.1    Li, J.2    Thamlikitkul, V.3
  • 71
    • 84861503214 scopus 로고    scopus 로고
    • High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategÿA preliminary study
    • Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategÿA preliminary study. Clin Infect Dis 2012;54:1720-6
    • (2012) Clin Infect Dis , vol.54 , pp. 1720-1726
    • Dalfino, L.1    Puntillo, F.2    Mosca, A.3
  • 72
    • 84872332208 scopus 로고    scopus 로고
    • Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gramnegative bacteremia
    • Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gramnegative bacteremia. Clin Infect Dis 2013;56:398-404
    • (2013) Clin Infect Dis , vol.56 , pp. 398-404
    • Vicari, G.1    Bauer, S.R.2    Neuner, E.A.3    Lam, S.W.4
  • 73
    • 72449141579 scopus 로고    scopus 로고
    • Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients
    • Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194-9
    • (2010) Int J Antimicrob Agents , vol.35 , pp. 194-199
    • Falagas, M.E.1    Rafailidis, P.I.2    Ioannidou, E.3
  • 74
  • 75
    • 34250025966 scopus 로고    scopus 로고
    • Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: First report of a multiclonal cluster
    • Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: First report of a multiclonal cluster. J Antimicrob Chemother 2007;59:786-90
    • (2007) J Antimicrob Chemother , vol.59 , pp. 786-790
    • Antoniadou, A.1    Kontopidou, F.2    Poulakou, G.3
  • 76
    • 84871618339 scopus 로고    scopus 로고
    • High rate of colistin resistance among patients with carbapenem-resistant klebsiella pneumoniae infection accounts for an excess of mortality
    • Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013;19:E23-30
    • (2013) Clin Microbiol Infect , vol.19
    • Capone, A.1    Giannella, M.2    Fortini, D.3
  • 77
    • 33846442436 scopus 로고    scopus 로고
    • Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy
    • Lodise TP Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63
    • (2007) Clin Infect Dis , vol.44 , pp. 357-363
    • Lodise Jr.., T.P.1    Lomaestro, B.2    Drusano, G.L.3
  • 78
    • 84871803445 scopus 로고    scopus 로고
    • Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: A systematic review and meta-analysis
    • Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: A systematic review and meta-analysis. Clin Infect Dis 2013;56:272-82
    • (2013) Clin Infect Dis , vol.56 , pp. 272-282
    • Falagas, M.E.1    Tansarli, G.S.2    Ikawa, K.3    Vardakas, K.Z.4
  • 79
    • 84873970562 scopus 로고    scopus 로고
    • Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: A before-after study
    • Arnold HM, Hollands JM, Skrupky LP, et al. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: A before-after study. Ann Pharmacother 2013;47:170-80
    • (2013) Ann Pharmacother , vol.47 , pp. 170-180
    • Arnold, H.M.1    Hollands, J.M.2    Skrupky, L.P.3
  • 80
    • 84868667406 scopus 로고    scopus 로고
    • A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia
    • Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012;16:R218
    • (2012) Crit Care , vol.16
    • Kollef, M.H.1    Chastre, J.2    Clavel, M.3
  • 81
    • 33845244357 scopus 로고    scopus 로고
    • Can we define the ideal duration of antibiotic therapy?
    • Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapÿSurg Infect (Larchmt) 2006;7:419-32
    • (2006) Surg Infect (Larchmt , vol.7 , pp. 419-432
    • Hedrick, T.L.1    Evans, H.L.2    Smith, R.L.3
  • 82
    • 38949101913 scopus 로고    scopus 로고
    • A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs ‡5 days in community-acquired intraabdominal infection
    • Basoli A, Chirletti P, Cirino E, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs ‡5 days in community-acquired intraabdominal infection. J Gastrointest Surg 2008;12:592-600
    • (2008) J Gastrointest Surg , vol.12 , pp. 592-600
    • Basoli, A.1    Chirletti, P.2    Cirino, E.3
  • 83
    • 84867330853 scopus 로고    scopus 로고
    • Improving known classes of antibiotics: An optimistic approach for the future
    • Bush K. Improving known classes of antibiotics: An optimistic approach for the future. Curr Opin Pharmacol 2012;12:527-34
    • (2012) Curr Opin Pharmacol , vol.12 , pp. 527-534
    • Bush, K.1
  • 84
    • 84869886623 scopus 로고    scopus 로고
    • Antibiotics in phase II and III clinical trials
    • Coates AR, Halls G. Antibiotics in phase II and III clinical trials. Handb Exp Pharmacol 2012;211:167-83
    • (2012) Handb Exp Pharmacol , vol.211 , pp. 167-183
    • Coates, A.R.1    Halls, G.2
  • 85
    • 81155162497 scopus 로고    scopus 로고
    • Diazabicyclooctanes (DBOs): A Potent New Class Of Non-beta-lactam Beta-lactamase Inhibitors
    • Coleman K. Diazabicyclooctanes (DBOs): A potent new class of non-beta-lactam beta-lactamase inhibitors. Curr Opin Microbiol 2011;14(5):550-5
    • (2011) Curr Opin Microbiol , vol.14 , Issue.5 , pp. 550-555
    • Coleman, K.1
  • 86
    • 74249108028 scopus 로고    scopus 로고
    • Three decades of beta-lactamase inhibitors
    • Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201
    • (2010) Clin Microbiol Rev , vol.23 , pp. 160-201
    • Drawz, S.M.1    Bonomo, R.A.2
  • 87
    • 77953552925 scopus 로고    scopus 로고
    • Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug- resistant infection
    • Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug- resistant infection. J Antimicrob Chemother 2010;65:1119-25
    • (2010) J Antimicrob Chemother , vol.65 , pp. 1119-1125
    • Hirsch, E.B.1    Tam, V.H.2
  • 88
    • 78649683457 scopus 로고    scopus 로고
    • Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non- beta-lactam beta-lactamase inhibitor
    • Stachyra T, Péchereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non- beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother 2010;54:5132-513
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 5132-5513
    • Stachyra, T.1    Péchereau, M.C.2    Bruneau, J.M.3
  • 89
    • 4444347175 scopus 로고    scopus 로고
    • In vitro activity of AVE1330A, an innovative broad-spectrum non- beta-lactam beta-lactamase inhibitor
    • Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non- beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother 2004;54:410-17
    • (2004) J Antimicrob Chemother , vol.54 , pp. 410-417
    • Bonnefoy, A.1    Dupuis-Hamelin, C.2    Steier, V.3
  • 90
    • 78650664486 scopus 로고    scopus 로고
    • Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae
    • Endimiani A, Hujer KM, Hujer AM, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55:82-5
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 82-85
    • Endimiani, A.1    Hujer, K.M.2    Hujer, A.M.3
  • 91
    • 79959280244 scopus 로고    scopus 로고
    • In vivo efficacy of a human-simulated regimen of ceftarolinecombined with nxl104 against extended-spectrum-betalactamase (esbl)- producing and non-esbl-producing enterobacteriaceae
    • Wiskirchen DE, Crandon JL, Furtado GH, et al. In vivo efficacy of a human-simulated regimen of ceftarolinecombined with NXL104 against extended-spectrum-betalactamase (ESBL)- producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:3220-5
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 3220-3225
    • Wiskirchen, D.E.1    Crandon, J.L.2    Furtado, G.H.3
  • 92
    • 84862573378 scopus 로고    scopus 로고
    • In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant gram-negative bacteria
    • Hirsch EB, Ledesma KR, Chang KT, et al. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012;56:3753-7
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 3753-3757
    • Hirsch, E.B.1    Ledesma, K.R.2    Chang, K.T.3
  • 93
    • 84872732888 scopus 로고    scopus 로고
    • Ceftazidime-avibactam: A novel cephalosporinbeta-lactamase inhibitor combination
    • Epub ahead of print
    • Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-Avibactam: A novel cephalosporin/beta-lactamase inhibitor combination. Drugs 2013; Epub ahead of print
    • (2013) Drugs
    • Zhanel, G.G.1    Lawson, C.D.2    Adam, H.3
  • 97
    • 84860121256 scopus 로고    scopus 로고
    • Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
    • Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012;10:459-73
    • (2012) Expert Rev Anti Infect Ther , vol.10 , pp. 459-473
    • Zhanel, G.G.1    Lawson, C.D.2    Zelenitsky, S.3
  • 98
    • 78650378928 scopus 로고    scopus 로고
    • Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates
    • Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011;66:48-53
    • (2011) J Antimicrob Chemother , vol.66 , pp. 48-53
    • Livermore, D.M.1    Mushtaq, S.2    Warner, M.3
  • 99
    • 78651462031 scopus 로고    scopus 로고
    • Antimicrobial activity of a novel aminoglycoside, ACHN-490, against acinetobacter baumannii and pseudomonas aeruginosa from new york city
    • Landman D, Kelly P, Backer M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 2011;66:332-4
    • (2011) J Antimicrob Chemother , vol.66 , pp. 332-334
    • Landman, D.1    Kelly, P.2    Backer, M.3
  • 100
    • 84866248918 scopus 로고    scopus 로고
    • Activity of plazomicin (ACHN-490) against MDR clinical isolates of klebsiella pneumoniae, escherichia coli, and enterobacter spp from athens, greece
    • Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012;24:191-4
    • (2012) J Chemother , vol.24 , pp. 191-194
    • Galani, I.1    Souli, M.2    Daikos, G.L.3
  • 101
    • 81555206664 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects
    • Cass RT, Brooks CD, Havrilla NA, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother 2011;55:5874-80
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 5874-5880
    • Cass, R.T.1    Brooks, C.D.2    Havrilla, N.A.3
  • 102
    • 84255201077 scopus 로고    scopus 로고
    • Antibiotics in development targeting protein synthesis
    • Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann NY Acad Sci 2011;1241:122-52
    • (2011) Ann NY Acad Sci , vol.1241 , pp. 122-152
    • Sutcliffe, J.A.1
  • 104
    • 84873740876 scopus 로고    scopus 로고
    • Update of dalbavancin spectrum and potency in the usa: Report from the sentry antimicrobial surveillance program (2011
    • Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: Report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013;75:304-7
    • (2013) Diagn Microbiol Infect Dis , vol.75 , pp. 304-307
    • Jones, R.N.1    Sader, H.S.2    Flamm, R.K.3
  • 105
    • 70350310343 scopus 로고    scopus 로고
    • Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates
    • Arhin FF, Draghi DC, Pillar CM, et al. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother 2009;53:4762-71
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 4762-4771
    • Arhin, F.F.1    Draghi, D.C.2    Pillar, C.M.3
  • 106
    • 77951748893 scopus 로고    scopus 로고
    • New lipoglycopeptides: A comparative review of dalbavancin, oritavancin and telavancin
    • Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: A comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-86
    • (2010) Drugs , vol.70 , pp. 859-886
    • Zhanel, G.G.1    Calic, D.2    Schweizer, F.3
  • 107
    • 84858166133 scopus 로고    scopus 로고
    • Tedizolid (TR-701): A new oxazolidinone with enhanced potency
    • Kanafani ZA, Corey GR. Tedizolid (TR-701): A new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 2012;21:515-22
    • (2012) Expert Opin Investig Drugs , vol.21 , pp. 515-522
    • Kanafani, Z.A.1    Corey, G.R.2
  • 108
    • 78649668302 scopus 로고    scopus 로고
    • Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations
    • Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010;54:5337-43
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 5337-5343
    • Locke, J.B.1    Finn, J.2    Hilgers, M.3
  • 109
    • 84858244397 scopus 로고    scopus 로고
    • In vitro activity of tedizolid (TR- 700) against linezolid-resistant staphylococci
    • Rodriguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR- 700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67:167-9
    • (2012) J Antimicrob Chemother , vol.67 , pp. 167-169
    • Rodriguez-Avial, I.1    Culebras, E.2    Betriu, C.3
  • 110
    • 62549099077 scopus 로고    scopus 로고
    • Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci
    • Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009;63:713-15
    • (2009) J Antimicrob Chemother , vol.63 , pp. 713-715
    • Livermore, D.M.1    Mushtaq, S.2    Warner, M.3    Woodford, N.4
  • 111
    • 78751689284 scopus 로고    scopus 로고
    • A phase 2 randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections (cSSSI
    • Prokocimer P, Bien P, Surber J, et al. A phase 2 randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections (cSSSI). Antimicrob Agents Chemother 2011;55:583-92
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 583-592
    • Prokocimer, P.1    Bien, P.2    Surber, J.3
  • 116
    • 0344022560 scopus 로고    scopus 로고
    • Preventing antimicrobial-resistant bacterial infections in surgical patients
    • Raymond DP, Kuehnert MJ, Sawyer RG. Preventing antimicrobial-resistant bacterial infections in surgical patients. Surg Infect (Larchmt) 2002;3:375-85
    • (2002) Surg Infect (Larchmt , vol.3 , pp. 375-385
    • Raymond, D.P.1    Kuehnert, M.J.2    Sawyer, R.G.3
  • 117
    • 38849164375 scopus 로고    scopus 로고
    • The Maxwell Finland Lecture: For the duration: Rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile
    • Rice LB. The Maxwell Finland Lecture: For the duration: Rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 2008;46:491-6
    • (2008) Clin Infect Dis , vol.46 , pp. 491-496
    • Rice, L.B.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.